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Abstract
Aims Statins have favourable effects on the vascular sys-
tem. However, few data are available regarding the effect of
these drugs on patients undergoing percutaneous coronary
intervention (PCI). We sought to determine the impact of
prior statin use on coronary blood flow after PCI in patients
with stable coronary artery disease (CAD) by using the cor-
rected thrombolysis in myocardial infarction (TIMI) frame
count (CTFC).
Methods A total of 80 consecutive eligible patients (mean
age: 60 ± 7 years, 65 % male) with the diagnosis of stable
CAD who were hospitalised for elective PCI were retro-
spectively enrolled in our study. The study population was
divided into two groups according to statin use at least
6 months before PCI. Group 1 comprised of 51 patients
(67 % male; mean age: 58 ± 4 years) taking statins and
group 2 comprised of 29 patients (62 % male; mean age:
60 ± 3 years) not taking statins. PCI was applied to de novo
type A lesions. CTFC was calculated for the treated vessels
at baseline and after PCI.
Results The two groups had similar characteristics in terms
of age, sex, concomitant medications, lesion characteristics,
pre-procedural CTFC, lipid parameters, and risk factors for
CAD. Post-PCI CTFC (16 ± 3 vs. 22 ± 5, p = 0.01) and hs-
CRP (2.1 ± 0.7 mg/l vs. 6.1 ± 2 mg/l, p = 0.01) in patients
receiving statins before PCI were significantly lower than in
patients without statin therapy. Multiple logistic regression
analysis showed that statin pre-treatment (OR 2.5, 95 % CI
1.2 to 3.8, p < 0.001) and hs-CRP level (OR 1.8, 95 % CI
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1.2 to 2.4, p = 0.001) were independent predictors of post-
PCI CTFC.
Conclusions In patients with stable CAD undergoing PCI,
receipt of long-term statin therapy was associated with im-
provement in epicardial perfusion after PCI.
Keywords Statin · Coronary blood flow · Stable coronary
artery disease
Introduction
Cholesterol reduction with HMG-CoA (3-hydroxy-3-
methylglutaryl coenzyme A) reductase inhibitors or statins
has been shown to improve mortality and cardiovascu-
lar morbidity in patients with established coronary artery
disease (CAD) [1, 2]. Recent studies suggest that the
incidence of early death and recurrent ischaemic events is
also reduced by statin therapy in acute coronary syndrome
(ACS) patients [3, 4]. However, few data are available
regarding the effect of these drugs on patients undergoing
percutaneous coronary intervention (PCI). Previous evi-
dence suggests that statins have various favourable effects
on the vascular system that are not directly related to their
impact on lipid metabolism. Beyond lowering lipids, statins
have favourable effects on platelet adhesion, thrombosis,
endothelial function, plaque stability, and inflammation
[5–8]. As with ACS, the vascular injury from coronary
angioplasty and stent placement induces platelet activa-
tion, thrombosis, and inflammation within the vessel wall
and the distal microvasculature. Therefore, in addition to
a long-term benefit associated with lipid lowering, statin
therapy might play a beneficial role early after PCI.
The thrombolysis in myocardial infarction (TIMI) frame
count (TFC) is a simple clinical tool for assessing quantita-
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tive indexes of coronary blood flow. The TFC is objective,
quantitative, reproducible, and sensitive to changes in coro-
nary flow [9]. It has been suggested that a higher TFC may
reflect disordered resistance vessel function or microvas-
cular dysfunction [9]. To our knowledge, there are no re-
ports regarding the effect of prior statin use on coronary
blood flow in patients with stable CAD undergoing PCI.
We sought to determine the impact of prior statin use on




A total of 80 consecutive eligible patients (mean age: 60 ±
7 years, 65 % male) with the diagnosis of stable CAD and
who were admitted for elective PCI were retrospectively in-
cluded in our study. The study population was divided into
two groups according to statin use at least for 6 months be-
fore PCI. Group 1 comprised 51 patients (67 % male; mean
age 58 ± 4 years) taking statins for at least 6 months before
PCI and group 2 comprised 29 patients (62 % male; mean
age: 60 ± 3 years) not taking statins. Statin treatment was
started 10 ± 2 months prior to the PCI. The type and dosage
of the statins used were as follows: (1) atorvastatin 79 % of
cases (mean dose 30 ± 10 mg/day); (2) pravastatin, 11 %
of cases (mean dose 20 ± 10 mg/day); and (3) simvastatin,
10 % of cases (mean dose 25 ± 10 mg/day).
PCI was performed based on the ongoing symptoms (re-
fractory angina) despite optimal medical therapy. Chronic
stable angina was defined as effort angina with objective
ischaemic evidence on thallium scintigraphy or exercise
testing over the past 6 months. Hypertension was defined
as a blood pressure of 140/90 mm Hg or more or treat-
ment with antihypertensive medication, current cigarette
smoking as active smoking, and family history of CAD
if patients had a first-degree male relative with evidence
of CAD <55 years of age or a female relative <65 years
of age. The body mass index was also measured. Ex-
clusion criteria were: acute coronary syndromes; severe
hepatic or renal dysfunction; diabetes mellitus; malig-
nant or inflammatory diseases; local or systemic infection;
anti-inflammatory drug use; and complex coronary lesions
(total occlusions, highly calcified lesion, left main coronary
artery lesion, restenosis, and vein graft lesion).
Adjunctive pharmacotherapy
All patients received 100 mg per day of acetylsalicylic acid
before intervention and unfractionated heparin during PCI
on a routine basis. Clopidogrel was given in accordance
with the guidelines. The glycoprotein IIb/IIIa inhibitors
were administered at the discretion of the operator. Un-
fractionated heparin bolus at 100 IU/kg (50–70 IU/kg, if
glycoprotein IIb/IIIa receptor inhibitor is administered) was
given to all patients and the periprocedural activated clotting
time (ACT) was measured. Unfractionated heparin dosage
was adjusted under ACT guidance (ACT in the range of
250–300 or 200–250 s, if glycoprotein IIb/IIIa receptor in-
hibitors are given).
Angiographic analysis
Selective coronary angiographic examinations were per-
formed by the standard Judkins technique. The coronary
diameters and stenosis percentages were measured by com-
puterised quantitative angiography in a biplane mode. An-
giographic assessment was always performed by two in-
dependent angiographers blinded to the patients’ clinical
data.
Only bare-metal stents with or without balloon predilata-
tion were used in this study. PCI was considered successful
if the final percent diameter stenosis was <50 %, with TIMI
grade 3 flow in the absence of recurrent ischaemia, myocar-
dial infarction, need for bailout stenting or urgent coronary
bypass surgery during hospitalisation, or death. Digital an-
giograms were then analysed by two independent, experi-
enced interventional cardiologists, blinded to the data. All
angiograms were assessed with respect to TIMI flow grade
and TFC for the vessel in which the intervention was per-
formed at baseline and after PCI.
Determination of TIMI flow grade and TIMI
frame count
TIMI flow grades have been described previously as grade
0, 1, 2, and 3 [10]. Coronary flow rates of all subjects
were documented by TFC for each major coronary artery
included in the study according to the method first described
by Gibson et al. [9]. The left anterior descending coronary
artery (LAD) is usually longer than the other major coro-
nary arteries and the TFC for this vessel is often higher. To
obtain a corrected TFC (CTFC) for the LAD, the TFC was
divided by 1.7. Intraobserver and interobserver variability
for CTFC was 1.3 ± 0.4 and 2.1 ± 0.6 frames, respectively.
Biochemical analyses
Fasting blood samples were taken from all patients in the
morning of the intervention day. Total cholesterol, triglyc-
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Table 1 Characteristics of the patients enrolled in the two groups
Statin group (n = 51) Control group (n = 29) p-value
Age (years) 58±4 60±3 0.3
Male gender, n (%) 34 (67) 18 (62) 0.1
Left ventricular ejection fraction, % 65±8 65±5 0.7
Current smokers, n (%) 17 (33) 12 (41) 0.5
Systemic hypertension, n (%) 26 (50) 16 (55) 0.1
Body mass index, kg/m² 23±4 25±4 0.2
Family history of CAD 24 (47) 14 (48) 0.4
Systolic BP, mm Hg 120±5 125±10 0.1








































Reference vessel diameter (mm) 3.0±0.1 3.2±0.2 0.2
Target vessel stenosis, % 80±10 85±10 0.09
Stent utilisation, n (%) 51 (100) 29 (100) 0.4
Stent diameter (mm) 3.4±0.2 3.5±0.3 0.1
Stent length (mm) 16±4 18±5 0.6
Dissection after PCI 0 (0) 0 (0) 1.0
Residual stenosis, % 15±5 20±5 0.3
Activated clotting time (s) 280±10 275±5 0.5
Pre-PCI CTFC (frames/s) 32±6 35±5 0.6
Post-PCI CTFC (frames/s)
Post-PCI heart rate, bpm
Post-PCI systolic BP, mm Hg













Total cholesterol (mmol/l) 4.3±0.2 4.1±0.3 0.1
LDL cholesterol (mmol/l) 2.4±0.6 2.2±0.5 0.1
HDL cholesterol (mmol/l) 1.1±0.3 1.0±0.2 0.4
Triglycerides (mmol/l) 1.5±0.2 1.5±0.2 0.6
hs-CRP (mg/l) 2.1±0.7 6.1±2 0.01
























Glycoprotein IIb/IIIa receptor blocker administration
(tirofiban), n (%)
4 (7) 3 (10) 0.8
CAD coronary artery disease; BP blood pressure; LAD left anterior descending artery; RCA right coronary artery; LCX left circumflex artery;
PCI percutaneous coronary intervention; CTFC corrected TIMI frame count; LDL low-density lipoprotein; HDL high-density lipoprotein;
ACE angiotensin-converting enzyme; hs-CRP high-sensitivity C-reactive protein
eride, high-density lipoprotein and low-density lipoprotein
(LDL) levels were also measured by an auto analyser. Con-
centrations of high-sensitivity C-reactive protein (hs-CRP)
were measured by latex-enhanced immunoturbidimetry.
Statistical analysis
Statistical analysis was performed using the SPSS statis-
tical package (SPSS, Inc., Chicago, Illinois). Continu-
ous variables were expressed as mean ± standard devia-
tion and categorical variables as %. While the chi-square
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Fig. 1 The comparison of corrected TIMI frame count (CTFC) be-
tween two groups
test or Fisher’s exact test was used for categorical values
between the two groups, differences between groups in nor-
mally and non-normally distributed variables were assessed
using the unpaired Student’s t test and the Mann-Whitney
U test, respectively. Analysis of covariance (ANCOVA)
was used to analyse the confounding effects of variables
on the comparisons of the groups according to statin use
before PCI. The multivariate analysis was used to define
independent factors influencing CTFC after PCI. The fol-
lowing selected variables were inserted into the multivariate
analysis: statin pre-treatment, age, body mass index, family
history of CAD, systolic and diastolic blood pressure, hs-
CRP level, hypertension, concomitant medications, smok-
ing, serum total cholesterol, LDL-cholesterol levels, lesion
length, residual percent stenosis, vessel diameter, and ves-
sel type. A p value of <0.05 was considered statistically
significant.
Results
The characteristics of the study population are listed in Ta-
ble 1. There was no statistically significant difference in
the baseline characteristics analysed, which included patient
age, sex, body mass index, left ventricular ejection fraction,
systolic and diastolic blood pressure, hypertension, smok-
ing, family history of CAD and various medication used.
Lipid parameters were also comparable between the two
groups (Table 1).
All the angiographic and procedural characteristics were
similar in the two groups (Table 1). A final TIMI 3 flow
was achieved in all patients. Angiographic complications
during the procedure did not occur. It reached the target
ACT levels during PCI in all patients. Glycoprotein IIb/
IIIa inhibitors were administered in 4 of 51 patients (7.0 %)
in the statin group and in 3 of 29 patients (10 %) in the
control group (p = 0.8). Intracoronary vasodilator agents
were not used.
Although pre-PCI CTFC values were similar between the
two groups (32 ± 6 vs. 35 ± 5, p = 0.6), post-PCI CTFC
in patients treated with statin before PCI was significantly
lower than the control group (16 ± 3 vs. 22 ± 5, p = 0.01,
Fig. 1). The hs-CRP level was significantly lower in the
patients taking statin in compared with the control group
(2.1 ± 0.7 mg/l vs. 6.1 ± 2 mg/l, p = 0.01) (Table 1). No
significant differences were found between the two groups
for any of the other analysed variables. Multiple logistic
regression analysis showed that only statin pre-treatment
(OR 2.5, 95 % CI 1.2 to 3.8, p < 0.001) and hs-CRP level
(OR 1.8, 95 % CI 1.2 to 2.4, p = 0.001) were independent
predictors of post-PCI CTFC.
Discussion
This study showed that receipt of chronic statin therapy
before PCI in patients with stable CAD is associated with
decreased CTFC of the target vessel, suggesting the im-
provement of microvascular function.
Conventional TIMI flow grading is a predictor of cardiac
outcome after acute myocardial infarction and PCI, but it
has several limitations [11]. The CTFC, another approach
to grade flow impairment, is an objective, quantitative, re-
producible, and sensitive index for coronary blood flow [9].
As indicated in our study, TIMI flow may appear normal
visually, but may correlate to abnormal CTFC. The CTFC
has been proposed to have incremental prognostic accu-
racy in predicting survival outcome with reperfusion ther-
apy [12]. This measurement was significantly correlated
with flow velocity measured with FloWire by several in-
vestigators during baseline conditions or hyperaemia [13].
So the CTFC may be an index of microvascular behaviour,
which reflects coronary vascular resistance [14]. Higher
CTFC values after PCI have also been found to be associ-
ated with poor clinical outcomes [15]. In addition to these
studies using thrombolysis or balloon angioplasty, in which
higher values of CTFC were associated with adverse clin-
ical outcome, there are several studies regarding CTFC’s
relevance in the current stent era [16–19]. In this study,
the post-PCI CTFC in patients receiving statin before PCI
was significantly lower than those of the patients not receiv-
ing statins. This finding may be attributed to the potential
beneficial effects of statins on coronary microcirculation.
Lipid profiles were similar between the two groups in
our study; therefore, the beneficial effects observed may be
considered independent of cholesterol lowering. Although
the present study was not designed to elucidate the poten-
tial mechanisms of the cardioprotective effect of the statins,
some possible mechanisms can be hypothesised. It is sug-
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gested that improvement of myocardial vascular function
by statins is not only a result of reduction in plasma lipids
but is also caused by some action on blood vessels other
than a lipid-lowering effect (so-called pleiotropic effects)
[5]. The pleiotropic effects encompass non-lipid mecha-
nisms that modify endothelial function, inflammation re-
sponses, plaque stability, and thrombus formation [20, 21].
Among those effects, improvement in endothelial function,
anti-thrombotic and anti-inflammatory actions may be cru-
cial for restoration of coronary blood flow after PCI, be-
cause those effects are consistent with a possible underly-
ing mechanism of slow coronary flow [22]. As in coronary
instability, vascular injury during PCI is associated with
a systemically measurable inflammatory response and the
degree of inflammation has been shown to be correlated
with cardiovascular risks [23, 24]. The improvement of
coronary blood flow associated with statin therapy might be
explained based on its anti-inflammatory effects, but with
the present evidence, this remains speculative.
Egashira et al. [25] demonstrated the improvement of
endothelium-dependent coronary vasomotion using acetyl-
choline-stressed quantitative coronary arteriography and
coronary flow velocity reserve using an intracoronary
Doppler catheter after 2 and 6 months of pravastatin treat-
ment in patients with dyslipidaemia. They speculated that
impaired endothelium-dependent vasomotion may play
a role in modulating myocardial perfusion in patients with
hypercholesterolaemia, typical-effort angina pectoris, and
critical stenosis of the epicardial coronary artery. It was
also found that pravastatin increased microvascular perfu-
sion in normocholesterolaemic patients with single-vessel
disease after successful PCI [26]. Briguori et al. [27]
showed that atorvastatin 80 mg loaded 24 hours prior to
PCI in statin-naive patients significantly reduced the risk
of periprocedural myocardial infarction as defined by ele-
vations of creatine-kinase myocardial enzyme and cardiac
troponin I. At 30 days, high-dose statin therapy reduced
the risk of periprocedural myocardial infarction by 44 %,
defined by both markers. The findings from NAPLES II
support the need to postpone the intervention in statin-
naive patients undergoing an elective procedure. These
findings may be attributed to the potential beneficial effects
of statins on CBF after PCI.
Limitations
There are several limitations of this study. First, it was a ret-
rospective study with a small number of patients. Larger
multicentre studies are needed to corroborate our findings.
Secondly, we could not estimate differences in efficacy
among the various statins because of the relatively small
numbers of patients in the study. There were substantial
differences in CTFC pre- and post-PCI in this study. This
would indicate that resting flow was impaired prior to PCI.
Resting flow usually remains constant up to subtotal le-
sions. A proximal stenosis must generally exceed 75 %
diameter narrowing before its resistance approximates that
of the resting coronary vascular bed resistance and begins to
reduce resting flow. In our study population, mean percent
diameter stenosis was 80 and 85 % respectively. This might
indicate that resting flow was impaired prior to PCI. The
final limitation was the impossibility of follow-up, which
could have informed us concerning the long-term clinical
outcomes.
Conclusions
In conclusion, the present study showed that statin therapy
before PCI in patients with stable CAD may have some
beneficial effects on coronary blood flow demonstrated by
CTFC. Further large-scale prospective randomised clinical
trials are needed to elucidate the underlying mechanisms
and clinical importance of these findings.
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